Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Biopsy, Endometrial cancer, Postmenopausal haemorrhage, Squamous cell carcinoma
Clinical narrative: Had a hysterectomy on Jul2022 which contained the extremely rare squamous cell carcinoma of the endometrium; extremely rare squamous cell carcinoma of the endometrium; Within 48 hrs of receiving 2nd dose I began sudden vaginal bleeding. This was my first vaginal bleeding post-menopause in at least 12-15 years/I then began having periods for the next few months; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 68-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 31Mar2021 at 14:00 as dose 2, single (Lot number: ER8733) at the age of 68 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Back/spine problems" (unspecified if ongoing), notes: Back/spine problems; "Back/spine problems" (unspecified if ongoing), notes: Back/spine problems; "Known allergies: Sulfa" (unspecified if ongoing), notes: Known allergies: Sulfa. The patient took concomitant medications. Vaccination history included: BNT162b2 (Dose 1, Single, Location of injection: Arm Left), administration date: 10Mar2021, when the patient was 68-year-old, for COVID-19 immunization.  The following information was reported: POSTMENOPAUSAL HAEMORRHAGE (medically significant) with onset 02Apr2021 at 11:00, outcome "not recovered", described as "Within 48 hrs of receiving 2nd dose I began sudden vaginal bleeding. This was my first vaginal bleeding post-menopause in at least 12-15 years/I then began having periods for the next few months"; ENDOMETRIAL CANCER (medically significant) with onset 2022, outcome "unknown", described as "Had a hysterectomy on Jul2022 which contained the extremely rare squamous cell carcinoma of the endometrium"; SQUAMOUS CELL CARCINOMA (medically significant) with onset 2022, outcome "unknown", described as "extremely rare squamous cell carcinoma of the endometrium". The events "within 48 hrs of receiving 2nd dose i began sudden vaginal bleeding. this was my first vaginal bleeding post-menopause in at least 12-15 years/i then began having periods for the next few months", "had a hysterectomy on jul2022 which contained the extremely rare squamous cell carcinoma of the endometrium" and "extremely rare squamous cell carcinoma of the endometrium" required physician office visit. The patient underwent the following laboratory tests and procedures: Biopsy: (unspecified date) No cancers; (Apr2022) Unusual cells. It was unknown if therapeutic measures were taken as a result of postmenopausal hemorrhage. Therapeutic measures were taken as a result of endometrial cancer, squamous cell carcinoma  Clinical Information: Within 48hrs of receiving second dose patient began sudden vaginal bleeding. This was her first vaginal bleeding post-menopause in at least 12-15 years. Patient saw her gyn same day who continued to monitor her for past year. Patient then began having periods for the next few months. Initial biopsy showed no cancers, however biopsy in Apr22 showed unusual cells. Had a hysterectomy on Jul22 which contained the extremely rare squamous cell carcinoma of the endometrium. All 3 of her oncologists had never seen this before and found only 100 cases worldwide. Patient now must have chemo and radiation as a preventative measure. Patient had not had any menstrual post menopause problems or bleeding prior to her second COVID vaccination. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Since the vaccination, patient has not been tested for COVID-19.